ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 38.9 Cr.
- Current Price ₹ 29.8
- High / Low ₹ 62.8 / 21.0
- Stock P/E
- Book Value ₹ 49.0
- Dividend Yield 0.00 %
- ROCE -4.73 %
- ROE -17.7 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.61 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -8.96% over last 3 years.
- Contingent liabilities of Rs.15.7 Cr.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 262 days.
- Working capital days have increased from 202 days to 300 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 154 | 354 | 220 | 145 | 93 | |
| 140 | 286 | 205 | 135 | 95 | |
| Operating Profit | 14 | 68 | 15 | 10 | -2 |
| OPM % | 9% | 19% | 7% | 7% | -2% |
| 1 | 1 | 10 | -1 | 2 | |
| Interest | 4 | 9 | 12 | 11 | 9 |
| Depreciation | 1 | 6 | 9 | 8 | 7 |
| Profit before tax | 10 | 54 | 3 | -11 | -16 |
| Tax % | 31% | 25% | 110% | -5% | -21% |
| 7 | 40 | -0 | -10 | -12 | |
| EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 |
| Dividend Payout % | 0% | 3% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -36% |
| TTM: | -36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | -46% |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -9% |
| Last Year: | -18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 13 | 13 | |
| Reserves | 73 | 73 | 63 | 51 | |
| 77 | 71 | 73 | 83 | ||
| 130 | 119 | 92 | 82 | ||
| Total Liabilities | 290 | 276 | 241 | 230 | |
| 93 | 88 | 58 | 57 | ||
| CWIP | 0 | 0 | 0 | 0 | |
| Investments | 0 | 0 | 0 | 0 | |
| 198 | 188 | 183 | 172 | ||
| Total Assets | 290 | 276 | 241 | 230 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 25 | 26 | -9 | -0 | ||
| -44 | -9 | 20 | -2 | ||
| 20 | -17 | -10 | 2 | ||
| Net Cash Flow | 0 | -0 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 105 | 138 | 184 | 262 | |
| Inventory Days | 59 | 118 | 183 | 331 | |
| Days Payable | 113 | 165 | 254 | 404 | |
| Cash Conversion Cycle | 51 | 91 | 113 | 188 | |
| Working Capital Days | 78 | 107 | 199 | 300 | |
| ROCE % | 9% | 1% | -5% |
Documents
Announcements
- Financial Year Results For The Year Ended 31.03.2025 30 May
-
Board Meeting Outcome for Outcome Of Board Meeting
30 May - Audited standalone and consolidated financial results for year ended 31 March 2025 with unmodified audit opinion.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
22 May - Annual Secretarial Compliance Report for FY 2024-25; minor delay in share capital audit submission resolved.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015
22 May - Board meeting on May 30, 2025, to approve FY25 audited financial results; trading window closed till 48 hours post meeting.
-
Disclosure Of Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated 26Th November, 2018- Fund Raising By Issuance Of Debt Securities By Large Corporate (LC)
24 Apr - ANG Lifesciences confirms non-applicability of SEBI circular for large entities as of March 31, 2025.
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)